Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study - 06/06/26
Highlights |
• | Retrospective data collection from 50 patients with mixed ATTRv in progression. |
• | Cardiac assessment ∼ 3 years after switching/adding RNAi to tafamidis monotherapy. |
• | With RNAi, cardiac parameters stabilized in 90% and improved in 10%. |
• | First real-world study showing cardiac benefit of switching to, or adding, RNAi. |
• | Neurologist and cardiologist collaboration is a priority for ATTRv management. |
Abstract |
Background |
Cardiomyopathy in hereditary transthyretin amyloidosis (ATTRv) is increasingly reported due to improved diagnostic techniques and increased clinician awareness. Optimal therapeutic strategies for mixed phenotypes remain challenging.
Aims |
To describe the changes in cardiac parameters among patients with ATTRv and cardiac involvement who had switched from stabilizer monotherapy to ribonucleic acid interference (RNAi) therapeutics or added RNAi to stabilizer monotherapy (switching/adding RNAi).
Methods |
Data from patients with ATTRv and confirmed cardiomyopathy who had started tafamidis monotherapy between 2010 and 2022 and switched to/added RNAi therapeutics (patisiran or vutrisiran) between 2018 and 2023 were retrospectively collected from October 2023 to May 2024. Functional, laboratory and imaging parameters were collected, and progression assessed according to the 2021 expert consensus on transthyretin amyloidosis with cardiomyopathy monitoring.
Results |
Fifty patients (median [interquartile range] age 63 [58–70] years; 66% male) from 10 French centres were included. Mean ± standard deviation follow-up durations on treatment were 3.8 ± 2.7 years for tafamidis monotherapy and 2.5 ± 1.9 years for RNAi (±tafamidis). Switching/adding RNAi was mainly for neurological progression ( n = 40; 80%). Under tafamidis monotherapy, 24% of patients worsened with simultaneous declines in clinical, laboratory and imaging parameters, while 76% were stable. After switching/adding RNAi, 90% of patients were stable, none worsened and 10% improved.
Conclusion |
This real-world French study is the first switch/add-on study in mixed phenotypes of ATTRv. It highlights the potential benefits of early switching/adding of RNAi in patients with insufficient cardiac response under tafamidis.
Le texte complet de cet article est disponible en PDF.Keywords : Patisiran, RNAi therapeutics, Tafamidis, Transthyretin cardiac amyloidosis, Vutrisiran
Plan
Vol 119 - N° 6-7
P. 452-460 - juin 2026 Retour au numéro
Article précédent
- Direct procurement and ex-situ assessment of donor hearts after controlled circulatory death: A French national pilot study
- Ali Akamkam, Maïra Gaillard, Simon Dang Van, Guillaume Gautier-Renard, Emeline Chu Van, Aurore Armand, Jean Christophe Venhard, Jacques Thes, Aurélien Vallée, Benoit Decante, Gaelle Cheisson, Corinne Antoine, Benoit Colsch, Julien Guihaire
- Tafamidis treatment in transthyretin cardiac amyloidosis: A retrospective cohort analysis of outcomes and associated factors
- Johanna Krief, Sylvain Aguilhon, Quentin Delbaere, Audrey Agullo, Caroline Padovani, Valentin Dupasquier, Christophe Hédon, Valentin Femenia, Nawel Aouni, Florence Leclercq, Jean-Luc Pasquie, Joana Pissarra, Lionel Moulis, Nicolas Chapet, François Roubille
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?